Publication: Primary Testicular Lymphoma: A Single Centre Experience
| dc.contributor.author | Kemal Y. | |
| dc.contributor.author | Teker F. | |
| dc.contributor.author | Demirag G. | |
| dc.contributor.author | Yucel I. | |
| dc.date.accessioned | 2020-06-21T09:43:06Z | |
| dc.date.available | 2020-06-21T09:43:06Z | |
| dc.date.issued | 2015 | |
| dc.department | OMÜ | en_US |
| dc.department-temp | Kemal, Y., Department of Medical Oncology, Samsun Education and Research Hospital, Samsun, 55100, Turkey -- Teker, F., Department of Medical Oncology, Faculty of Medicine, 19 Mayis University, Samsun, 55139, Turkey -- Demirag, G., Department of Medical Oncology, Faculty of Medicine, 19 Mayis University, Samsun, 55139, Turkey -- Yucel, I., Department of Medical Oncology, Faculty of Medicine, 19 Mayis University, Samsun, 55139, Turkey -- | en_US |
| dc.description.abstract | Aim: Primary testicular lymphoma (PTL) is an uncommon and aggressive form of extranodal non-Hodgkin's lymphoma (NHL). We aimed to analyse the clinicopathological characteristics and outcomes of our PTL cases. Materials and Methods: A review was made of the medical records of 339 NHL patients who were treated in the Medical Oncology Department between January 2005 and December 2013. Results: 8 PTL patients were identified from the 339 NHL patients. The average age of the patients was 67.7 ± 7.9 years (range 53-79 years). The mean follow-up time was 24.8 months (range 7-98 months). Inguinal orchiectomy was performed as a diagnostic and initial therapy and all the patients underwent 4-6 cycles of chemoimmunotherapy consisting of cyclophosphamide, doxorubicin, vincristine and prednisone plus rituximab. 4 of 8 patients received intrathecal prophylactic chemotherapy and 6 of 8 patients continued contralateral testis irradiation. Relapse occured in only 1 patient in central nervous system after 6 months who had not received intrathecal prophylaxis. No contralateral testis relapse was observed. Conclusions: Primary testicular NHL is an uncommon entity and we evaluated 8 patients; with one relapse in central nervous system and no relapse in the contralateral testis. Copyright © Experimental Oncology, 2015. | en_US |
| dc.identifier.endpage | 226 | en_US |
| dc.identifier.issn | 1812-9269 | |
| dc.identifier.issue | 3 | en_US |
| dc.identifier.pmid | 26422109 | |
| dc.identifier.startpage | 223 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/5257 | |
| dc.identifier.volume | 37 | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Morion LLC | en_US |
| dc.relation.journal | Experimental Oncology | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Contralateral Scrotal Irradiation | en_US |
| dc.subject | Intratechal Chemotherapy | en_US |
| dc.subject | Primary Testicular Lymphoma | en_US |
| dc.title | Primary Testicular Lymphoma: A Single Centre Experience | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication |
